Details of the Drug Combination

General Information of Drug Combination (ID: DC4NDKD)

• Drug Combination Name: DFN-15 + Terameprocol
• Indication: Lung adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  DFN-15 (DM3BF9B): N.A.
  Terameprocol (DMC3P45): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: MDA-MB-231
  Zero Interaction Potency (ZIP) Score: 1.16
  Bliss Independence Score: 4.18
  Loewe Additivity Score: 0.68
  LHighest Single Agent (HSA) Score: 0.68

Molecular Interaction Atlas of This Drug Combination

Indication(s) of DFN-15

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[2]

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DC17SWV	U251	Investigative	[4]
Clear cell renal cell carcinoma	DCUYSN2	A498	Investigative	[4]
Glioma	DCORIMS	SF-539	Investigative	[4]
Adenocarcinoma	DCU5KYI	NCIH23	Investigative	[1]
Adenocarcinoma	DC1L534	HCC-2998	Investigative	[1]
Pleural epithelioid mesothelioma	DC69APN	NCI-H226	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.